Pharmacology & Toxicology

← Back to Mechanisms by Origin Domain

The study of how chemical substances interact with biological systems — drug action, dose-response relationships, pharmacokinetics and pharmacodynamics, adverse effects, and mechanisms of toxicity.

Reviewed origins (28)

These attributions have been reviewed as historical or practice origins and promoted to mechanism frontmatter.

• Active-Site Inhibitor — Places a blocker at an active site to prevent substrate occupation and transformation.
• Bayesian Dose Forecasting — A forecasting method that updates exposure-response predictions as new observations arrive.
• Clearance Acceleration Protocol — Speeds the receiver's own clearance of an accumulated surplus so the system falls back below the ceiling faster — and the depleted second resource is given room to rebuild.
• Combination Therapy Regimen — Combines treatments whose mechanisms, timing, or dosing are expected to reinforce one another while monitoring safety and antagonism.
• Compartment Model — Abstracts a system into a few well-bounded compartments linked by transfer rates, so accumulation and turnover follow from residence times instead of being watched flow by flow.
• Compartmental PK/PD Model — A model that represents exposure as movement through one or more compartments before linking exposure to response.
• Competitive Occupancy Inhibition — Occupies the target pathway's own control point with a rival that engages the site but does nothing, so the real activator can no longer bind it at the former rate — a surmountable brake set by dose.
• Competitive Receptor Antagonist — Uses a nonactivating ligand to occupy a receptor so an agonist cannot trigger the downstream response.
• Contact Time Reduction — Shrinks exposure by cutting how long the receptor stays in contact at the interface, lowering cumulative dose without changing the concentration present.
• Dosage Window Protocol — Sets a standing acceptable range for a managed input — a floor for effect and a ceiling for harm — with codified rules for correcting back into it.
• Dose-Response Curve Mapping — Charts the receiver's net response across the full range of input dose, locating the band where more helps and the point where it flips to harm.
• Dose-Response Inversion Curve — Maps the whole input-to-outcome relationship, marking the dose where rising input stops helping and starts harming — and why the harm runs away once it begins.
• Drug Interaction Screening — Checks whether medications, treatments, or supplements create harmful combined effects before they are co-prescribed or co-used.
• Effect-Compartment Lag Model — Inserts a hypothetical effect-site compartment so measured exposure and observed response can be separated by a modeled time lag.
• Exposure Dose Curve — Maps how response changes across the full range of an input — from no effect, through the useful zone, to diminishing returns and harm — so any single level can be read off the curve.
• Exposure–Response Simulation — Runs candidate input regimens forward through the coupled exposure-response model to project their trajectories against the target window before any is tried live.
• Hormetic Microdose Protocol — Delivers repeated sub-damage doses of a stressor so the system overcompensates and builds tolerance it would never develop at rest.
• Inhibitor Titration and Taper — Ramps inhibition up in small steps until the target sits in its objective band, then steps it back down gradually so the pathway doesn't rebound on release.
• Minimum Effective Dose Review — Periodically re-examines a standing input to find the lowest level that still works, deliberately shedding dose to reduce off-target burden without losing the effect.
• Nonlinear Breakdown Review — Sweeps toward the limits to find where additivity breaks and routes the exceptions to a nonlinear model.
• Physiologically Based Exposure–Response Model — A mechanism-grounded model that uses explicit pathways or compartments to support exposure-response prediction and extrapolation.
• Population PK/PD Covariate Model — Represents systematic between-subject variability by tying model parameters to covariates, yielding population priors that individualize before any measurement.
• Post-Market Surveillance Registry — A standing database that enrolls every deployed unit and links it to its later outcomes, giving field harms a denominator so a rising signal trips a defined action threshold.
• Process Analytical Technology Loop — Closes the loop on a live separation: in-line sensors read the forming phases in real time and feed back to adjust conditions on the fly, holding the process on its target trajectory.
• Pulse Dose — Implements a bounded pulse of treatment, training, stimulus, or effort under domain-specific safety rules.
• Pulse Dosing — Delivers input in intermittent high pulses separated by recovery gaps so response stays strong without tolerance, toxicity, or saturation.
• Route–Form–Timing Optimization — Raises the fraction that arrives usable by changing how the input is delivered — its route, its form, and its timing — instead of increasing the amount supplied.
• Stagewise Availability Assay — Measures how much of the input remains in usable form at each stage of the path, turning one supplied figure into a stagewise availability profile with error bars.

Also Draws from This Domain (38)

These mechanisms have another primary origin but were reviewed as also drawing materially from this domain.

• Aseptic Field Protocol — Establishes a protected sterile field defined by a strict clean/contaminated binary, and governs it with an 'only sterile may touch sterile' contact rule.
• Biomarker Monitoring — Uses observable biological indicators as proxies for health status, exposure, disease progression, or treatment response.
• Challenge-Panel Cross-Reactivity Test — Tests the selector against near-neighbor, decoy, or vulnerable non-target cases to reveal where discrimination collapses.
• Clinical Alternative Pathway Review — When a standard care pathway is contraindicated or unavailable, reviews evidence-based alternatives against the patient's therapeutic goal and their path-specific risks, then selects a safe substitute.
• Clinical Indication Criteria — Defines which patients, conditions, and timing an intervention is valid for — and the contraindications and preconditions that place a case outside it — so a treatment isn't given where it was never indicated.
• Clinical Titration Adjustment — Adjusts a therapy by small, observed increments toward the patient's response, with a clinician gate holding veto over every step.
• Clinical Titration Protocol — Implements titrated intervention through professionally governed starting levels, adjustment increments, monitoring intervals, contraindications, and stop conditions.
• Clinical Treatment Adjustment — Adjusts a treatment's dose, intensity, timing, or support in response to a patient's changing state and side effects — monitored closely and reversed the moment the change does harm.
• Combination Therapy Protocol — Coordinates multiple treatments so one increases the efficacy, tolerability, reach, or durability of another.
• Decoy Binding or Sink — Plants a sacrificial look-alike that soaks up a pathway's activator before it can reach the real mechanism, starving that one pathway while others keep their supply.
• Design for Cleaning Access — Builds reachability into the interface up front — ports, removable panels, service clearances — so removal stays possible over the whole lifecycle.
• Disease-Stage Treatment Protocol — Implements the archetype when diagnosis, treatment intensity, contraindications, monitoring, or follow-up differ across disease stage or recovery phase.
• Double-Blind Trial Protocol — A protocol that masks both recipients and delivery personnel from knowing active versus comparator assignment.
• Drug Holiday — A clinician-supervised, consent-based pause in a chronic treatment, taken under safety cover so responsiveness or tolerance can be reassessed.
• Emergency Unblinding Procedure — A controlled pathway that reveals one participant's assignment when safety requires it, under authorization and with a permanent record.
• Exposure Rotation — Rotates among several interchangeable inputs so no single one repeats often enough to lose its bite, spreading exposure instead of pausing it.
• Inhibitor and Poison Screen — Tests incoming cases and operating conditions for the contaminants, conflicts, and incompatibilities that would suppress or corrupt the facilitator — catching them before they reach it.
• Intensity Ladder Trial — Climbs a predeclared ladder of intensity rungs from the bottom, stopping at the first rung that reliably produces the wanted effect.
• Medication Dose Calibration — Dials an individual's dose to their own observed response and adverse signals, titrating under professional oversight until the effect lands in target without tipping into harm.
• Medication Taper Schedule — A clinical mechanism for reducing dose or frequency over time under qualified supervision when abrupt cessation could cause withdrawal or rebound.
• Noncompetitive or Allosteric Inhibition — Caps a mechanism's output by binding a separate control site and changing its state, so piling on more input can't overcome the block.
• Noninferiority Margin Protocol — Fixes, before any data are seen, the largest performance shortfall from the comparator that will still count as acceptable — turning 'not meaningfully worse' into a pre-committed number when the candidate wins on cost, access, or convenience.
• Observation Dose–Response Test — Deliberately varies the observation dose — frequency, intensity, invasiveness — and plots the target's response against it, exposing the thresholds and nonlinearities that reveal how hard you can watch before the measurement dominates what it measures.
• Paired Half-Life Probe — Measures or estimates how long each component of a signal bundle remains salient, valid, or operationally influential.
• Perturbation Response Sweep — Applies graded disturbances of increasing size along a control axis to map how response scales — proportional, amplified, cascading, or cross-scale.
• Physiological Regulation Protocol — A clinical protocol that keeps a physiological variable inside a therapeutic window by titrating a corrective intervention in graded steps and escalating care when titration cannot hold the range.
• Policy Intensity Band — Sets policy strength within an effective and legitimate range.
• Quarantine or Isolation Protocol — Holds a suspect source or reservoir in enforced isolation — under an explicit trigger and release rule — so its accumulated burden cannot spread or contaminate what lies downstream while it is worked.
• Reintroduction Ramp — Brings a stimulus back gradually from a low starting level up to a capped ceiling, so the old tolerance pattern is not rebuilt on the first day of return.
• Reset Period Protocol — Sequences the full reset — trigger, protected pause, and scheduled follow-up — so tolerance detection, recovery, and controlled return happen in order rather than ad hoc.
• Residual Tail Washout Check — Confirms that prior-condition residue has dissipated enough before a later condition is interpreted.
• Response-Curve Calibration — Maps how response varies with input timing and dose so the peak-response frequency and window can be read off an empirical curve.
• Selectivity Window Test — Sweeps the selector across its control variable to map where it separates target from non-target, locating the operating window in which selectivity holds and the edges where it collapses.
• Sham or Placebo Control — An inactive or alternative comparator designed to preserve credibility and mask active-condition identity.
• Side-Path Suppression — Raises the fraction of the intermediate that exits down the desired branch by blocking the competing side-paths that leak, divert, or spoil it.
• Single-Blind Participant Masking — Masks the recipient alone from knowing which condition they received, while implementers stay informed.
• Solvent–Antisolvent Shift — Changes solvent quality — typically by adding an antisolvent — so that selected constituents lose solubility and precipitate or split off while others stay dissolved.
• Stimulus–Response Pilot — Runs a bounded trial across several predeclared stimulus levels to fit the shape of the input-to-response curve, with its uncertainty and its subgroup differences attached.